Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

Officer, Robert I. Blum. "We are looking forward to now expanding our collaboration with Amgen to provide for the advancement of this novel cardiac muscle activator into studies that are designed to further assess the clinical benefit of this exciting compound. Amgen has consistently demonstrated a successful track record with first-in-class mechanism compounds and we are pleased to be moving forward together."

Conference Call / Webcast

Cytokinetics will host a conference call on Tuesday, May 26, 2009 at 9:00 a.m. Eastern Time. The conference call will be simultaneously webcast and can be accessed in the Investor Relations section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call is also accessible via telephone to investors, members of the news media and the general public by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 11656519. An archived replay of the webcast will be available via Cytokinetics' website until June 9, 2009. The replay will also be available via telephone by dialing (800) 642-1687 (United States and Canada) or (706) 645-9291 (international) and typing in the passcode 11656519 from May 26, 2009 at 1 p.m. Eastern Time until June 9, 2009.

Background on the Collaboration

In December 2006, Cytokinetics and Amgen entered into a strategic collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. In connection with the execution of the collaboration and option agreement, Amgen paid Cytokinetics approximately $75 million, comprised of a non-refundable up-front license and technology access fee of $42 million and equity investment of approximately $33 million. At that time, Am
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Skeletal dysplasia is a group of rare diseases ... and cartilage. Its onset hits at the fetal ... mutation in the gene encoding fibroblast growth factor ... types of skeletal dysplasia, thanatophoric dysplasia (TD), a ... birth and is often lethal, and achondroplasia (ACH), ...
(Date:9/18/2014)... loss and diabetes prevention, could actually hasten the development ... it in a surprising way: by changing the composition ... population of bacteria residing in our intestines. These findings, ... published today in Nature . Among other things, ... Department, who led this research together with Prof. Eran ...
(Date:9/18/2014)... everything we touch in the course of a ... even medicines, rely on the chemical industry to ... and farm products into valuable chemicals that are ... scientist Dr Sarina Sarina, who achieved outstanding progress ... at ambient temperature using light instead of fossil ...
(Date:9/18/2014)... 2014 Silicon-valley Electronic Data Capture (EDC) ... TXT , the latest addition to Clinovo’s CRO Partnership ... Organization (CRO) Program, Clinovo further expands its global reach ... ClinCapture training, we are now able to build studies ... “We can also rely on Clinovo to fully support ...
Breaking Biology Technology:Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Using solar energy to turn raw materials into ingredients for every day life 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3
... Regulus Therapeutics Inc ., a biopharmaceutical company leading the ... announced that it has identified a third microRNA target ... milestone payment from GSK. This selection represents another significant ... which is focused on the discovery and development of ...
... , Daval International announced the ... double blind Phase II,Study, Treating Patients with Bladder ... Standard clinical,measures and assessment scores recorded on patients ... be used to investigate safety,efficacy and response to ...
... ReSearch Pharmaceutical Services, Inc. (RPS), a next ... clinical development solutions to the biopharmaceutical and medical ... to its Operational and Senior Management team.   ... Chief Information Officer and Executive Vice President, Clinical ...
Cached Biology Technology:Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 3RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3
(Date:9/17/2014)... of Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by ... in normal accompanying cells in colorectal tumors. Analysis ... colorectal tumors, predict the evolution of the patient ... relapses. , Biomarkers , Colorectal ... considering both sexes. About 30,000 new cases are ...
(Date:9/17/2014)... growing significantly faster since the 1960s. The typical development ... they have accelerated -- by as much as 70 ... out by scientists from Technische Universitt Mnchen based on ... continuously observed since 1870. Their findings were published recently ... "forest dieback" was a hot topic, with the very ...
(Date:9/16/2014)... The risk of severe maternal morbidity amongst women ... suggests a new study published today (17 September) ... and Gynaecology . , Australians generally enjoy high ... that health disparities exist, in particular between indigenous ... aimed to explore the independent impact of socioeconomic ...
Breaking Biology News(10 mins):Five genes to predict colorectal cancer relapses 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... investigated the rates of evolution of the two key characteristics ... order to fly, hulking meat-eating dinosaurs had to shrink in ... wings. "We were really surprised to discover ... at the origin of Paraves," said Mr Puttick of Bristol,s ...
... subtype of innate lymphoid cells in human spleen essential ... the prestigious journal Nature Immunology , clears the ... more efficient vaccines against encapsulated bacteria, considered highly virulent., ... research group at IMIM (Institut Hospital del Mar d,Investigacions ...
... discovered a ,microbial Pompeii, preserved on the teeth of ... discovery is the dental calculus (plaque) which preserves bacteria ... teeth, effectively creating a mineral tomb for microbiomes. ... oral cavity carries numerous opportunistic pathogens and that periodontal ...
Cached Biology News:New insights into the origin of birds 2Researchers have identified a novel immunological mechanism of great importance for vaccine developm 2Scientists unlock a 'microbial Pompeii' 2Scientists unlock a 'microbial Pompeii' 3
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
This Malachite Green Phosphate Detection Kit...
Request Info...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
Biology Products: